To summarize, this is the first study showing that modulating PDK4 can affect rituximab‐induced cell apoptosis on DLBCL. Notably, we identified the potential that PDK4 promotes proliferation and rituximab resistance in DLBCL cells by mediating metabolic reprogramming. Here, PDK4 is linked to diffuse large B-cell lymphoma.